Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, announced that it will provide student conference sponsorship for a second year to the Future of Hearing Healthcare Conference, which will allow up to 75 audiology graduate students to attend the event at no cost.
Otolith Labs’ noninvasive vestibular system masking (nVSM) technology is designed to provide acute treatment for vestibulogenic vertigo.
This level of sound surpasses the average auditory threshold of pain and greatly exceeds the volume of a jet engine taking off. Exposure at this level is capable of causing not only permanent hearing loss but also migraine, balance, and other auditory symptoms, according to a statement issued by ASHA.
“Objective testing showed evidence of a balance disorder that affects the inner ear and a unique pattern of cognitive and behavioral dysfunction,” said Dr Michael E. Hoffer, professor of otolaryngology and neurological surgery. “This cluster of auditory and neurological symptoms, along with associated psychological issues, does not resemble more classic traumatic brain injury (TBI) based on our team’s vast experience in this area.”
Read More
InnerScope and Erchonia are reported to have received approval under FDA regulations from an Institutional Review Board (“IRB”) for the initial clinical trial of the effect of Erchonia’s low-level laser therapy technology on the relief of tinnitus symptoms.
Read More
Researchers from Chalmers University of Technology have developed a new device using bone conduction technology that is said to offer “significant advantages” over current tests.
Read More
By comparing the effects of seliforant to meclizine, a drug with known anticholinergic side effects, and placebo, the SENS-111-202 study aims to confirm the absence of anticholinergic effects such as sedation and memory loss in patients receiving seliforant.
Read More
It has been estimated that 1 in 100 people around the world have a congenital inner ear condition known as semicircular canal dehiscence, a thinning of the bone enclosing the inner ear that can lead to vertigo in response to certain sounds, changes in atmospheric pressure, or coughing.
Read More
Anc-AAVs are in silico-designed adeno-associated viral vectors (AAVs), first developed in the laboratory of Dr Luk H. Vandenberghe, assistant professor of ophthalmology at Harvard Medical School, and director of the Grousbeck Gene Therapy Center at Massachusetts Eye and Ear.
Read More
This gift reportedly represents one of the country’s largest philanthropic investments ever to advance research on hearing and hearing loss, a significant public health problem impacting one-third of the world’s population over age 65.
Read More
An interactive website developed by health psychology and primary care researchers at the University of Southampton has been shown to reduce dizziness amongst adults aged 50 and above, the university announced on its website.
Read More
Researchers at Icahn School of Medicine at Mount Sinai have developed a treatment for people who suffer from Mal de Debarquement Syndrome (MdDS), a rare but debilitating balance disorder.
Read More
A leading balance expert will facilitate 3-day course in VNG/ENG, including hands-on demonstration of the latest technology.
Read More